simmitecan + thalidomide

**Simmitecan + thalidomide** is a combination regimen under clinical investigation for advanced solid tumors, primarily colorectal cancer. Simmitecan is a novel, potent lipophilic camptothecin derivative that acts as an inhibitor of **topoisomerase I**, resulting in anti-tumor activity by interfering with DNA replication and transcription in cancer cells. Thalidomide is a well-established immunomodulatory and anti-angiogenic agent that reduces inflammation and inhibits tumor vasculature formation, also modulating the immune response in the tumor microenvironment. Preclinical data and Phase Ib trial findings indicate this combination potentially enhances anti-tumor efficacy and may mitigate simmitecan-induced gastrointestinal toxicity through thalidomide’s mechanisms. The combination is given as intravenous simmitecan every two weeks, with oral thalidomide at varying doses. Preliminary efficacy in advanced colorectal cancer has been observed, particularly in patients previously treated with irinotecan[1][2][3].

Other names

simmitecanthalidomide